Eric Halioua

Outlook Microsoft Office 365 Mobile Friendly Google Tag Manager Google Maps Google Analytics Google Font API

cancer immunotherapy therapeutic vaccines clinical development plasmacytoid dendritic cells neoantigens biotechnology research pdc*vac technology pdc*line non-small cell lung cancer pdc*lung trial melanoma immunotherapy pdc*mel colorectal cancer therapy neoantigen cancer vaccine clinical trials off-the-shelf vaccines immune checkpoint inhibitors pd-1 synergy antigen-specific t cells cd8+ t cell response t cell priming cancer treatment scalable production gmp manufacturing biotech innovations cancer vaccine technology patient-specific therapies preclinical studies cancer research biotechnology cancer vaccine candidates tumor antigens clinical proof of concept phase i/ii trials immune monitoring investor opportunities biopharmaceutical collaborations regulatory compliance immunotherapy advancements treatment efficacy vaccine development biopharma funding advanced therapy medicinal product cell therapy tumor immune response critical clinical results biopharmaceutical industry therapeutic candidates safety & tolerability investment opportunities scientific publications immune system enhancement health care health wellness & fitness hospital & health care